A common complication of using thrombolytic drugs S

A) Patients with hypertension
Low molecular weight heparin (LMWH) is not primarily used to treat hypertension. Hypertension (high blood pressure) is typically managed with antihypertensive medications like ACE inhibitors, beta-blockers, diuretics, or calcium channel blockers. LMWH is an anticoagulant, which works to prevent blood clots rather than controlling blood pressure.

B) Patients with asthma
LMWH is not typically used to treat asthma. Asthma is a chronic respiratory condition that is usually managed with bronchodilators (e.g., albuterol) and anti-inflammatory drugs such as corticosteroids. While patients with asthma may be at risk for blood clots under certain conditions (e.g., severe asthma exacerbations, immobility), LMWH is not a first-line treatment for asthma.

C) Patients with diabetes
While people with diabetes may be at an increased risk of developing blood clots, LMWH is not specifically used to treat diabetes. Diabetes is typically managed with insulin, oral hypoglycemic agents, lifestyle modifications, and other medications to control blood glucose levels. LMWH is an anticoagulant used for conditions that require prevention of clot formation, such as deep vein thrombosis (DVT).

D) Patients with deep vein thrombosis (DVT)
LMWH is commonly prescribed to patients with deep vein thrombosis (DVT). DVT occurs when a blood clot forms in a deep vein, usually in the legs. LMWH is a type of anticoagulant that prevents the formation of further clots by inhibiting factors involved in blood clotting. It is especially effective for patients with DVT or those at high risk for thromboembolic events, such as after surgery or during prolonged immobility. LMWH provides more predictable anticoagulation and requires less frequent monitoring than unfractionated heparin, making it ideal for outpatient management and in hospital settings.

A) Subcutaneous:
The subcutaneous route involves administering medication into the layer of fat and connective tissue beneath the skin. This method is used for drugs that require slower absorption, such as insulin or certain vaccines.

B) Intramuscular:
The intramuscular route involves injecting medication directly into a muscle. This allows for faster absorption compared to subcutaneous injections, making it ideal for drugs that need to be absorbed quickly, such as vaccines or certain antibiotics.

C) Via a nasogastric tube:
Administering drugs via a nasogastric tube is not considered a parenteral route. The nasogastric (NG) tube delivers medications directly into the stomach via the gastrointestinal tract, which is not part of the parenteral system. Parenteral routes are those that bypass the digestive system, like injections.

D) Intradermal:
The intradermal route involves injecting medication just under the skin, in the dermis. This is typically used for allergy testing or tuberculosis screenings. It is a parenteral route because it bypasses the digestive system.

E) Intravenous:
The intravenous route involves injecting medication directly into a vein, offering rapid absorption and fast onset of action. This method is ideal for critical or emergency situations where immediate medication effects are necessary.